Supporting a clinical relevance for CD44 targeting in T-ALL, aberrant expression of CD44 has been detected in different T-ALL subtypes, and abnormally high expression levels of CD44 have been associated with organ infiltration in T-ALL patients [251] and with T-ALL chemoresistance [252]. This evidence concerns the gene CD44 and acute lymphoblastic leukemia.